Auxilium Pharmaceuticals promotes James Tursi

Becomes chief medical officer having worked for US firm since 2009

Auxilium Pharmaceuticals, a US specialist biopharmaceutical company, has promoted James Tursi to chief medical officer. He has worked for Auxilium since March 2009 and has been responsible for the oversight of clinical development, clinical operations, biometrics and medical writing.

Tursi entered the pharmaceutical industry in 2004 as a medical director for Procter and Gamble Pharmaceuticals. He worked on several products and therapeutic areas, including female sexual dysfunction, overactive bladder, and osteoporosis. His responsibilities included clinical development and medical affairs. He moved to GlaxoSmithKline Biologicals in 2006 and directed all Medical Affairs responsibilities for cancer vaccines in North America.

You may also like

Packaging

ProMach Pharma presents new equipment at Pack Expo Las Vegas

Several new systems will be on exhibit for the first time, alongside other advanced processing and packaging equipment for pharmaceuticals, biopharmaceuticals, nutraceuticals, medical devices and more
Pharmaceutical

CPHI Frankfurt 2025 to welcome more than 60,000 pharma professionals with expanded focus on innovation and sustainability

Returning to Germany from 28-30 October, CPHI Frankfurt 2025 will unite the global pharmaceutical supply chain with more than 2000 exhibitors, six content theatres and new feature zones
Manufacturing

Continuous innovation: redefining the future of pharmaceutical manufacturing

In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
Pharmaceutical

Keystone Folding Box Co. unveils Key-Pak Plus

Designed to protect children and empower seniors, it achieves top U.S. safety ratings and meets global accessibility standards
Pharmaceutical

Bavarian Nordic launches chikungunya vaccine Vimkunya in the UK

The UK announcement of the recombinant vaccine follows recent approval by the MHRA in May 2025
Research & Development

Servier and IDEAYA Biosciences join forces to bring a promising new eye cancer treatment to patients across the globe

Servier and IDEAYA Biosciences have entered into an exclusive license agreement for regulatory and commercial rights to darovasertib outside the US
Pharmaceutical

Atelerix and Rodon Global enter new partnership to create cryo-free logistics

The initial agreement will be to incorporate Atelerix’s non-cryogenic cell preservation technology into Rodon's international freight and logistics services for drug discovery and clinical trials
Subscribe now